Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 17;117(3):229-33.
doi: 10.1161/CIRCRESAHA.117.306306.

Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?

Cristina Sanina  1 , Joshua M Hare  2
Affiliations

Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?

Cristina Sanina et al. Circ Res. .

Abstract

Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

Keywords: cell- and tissue-based therapy; chronic heart failure; clinical trial; heart disease; mesenchymal stem cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1. 34 MSC clinical trials for heart disease
Number of MSC clinical trials according trial phase (A). Total number of patients enrolled or estimated to be enrolled according trial phase (B). Average number of patients enrolled or estimated to be enrolled per trial (C). The route of cell administration in 35 clinical trials (intravenous (IV), intracoronary (IC), intramyocardial (IM), transendocardial (TE)) (D).
See this image and copyright information in PMC

References

    1. Karantalis V, Hare JM. Use of Mesenchymal Stem Cells for Therapy of Cardiac Disease. Circulation research. 2015;116:1413–1430. - PMC - PubMed
    1. Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP group Dw. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ. 2014;348:g2688. - PMC - PubMed
    1. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11–5. - PMC - PubMed
    1. Hare JM, Sanina C. Bone Marrow Mononuclear Cell Therapy and Granulocyte Colony-Stimulating Factor for Acute Myocardial Infarction: Is it Time to Reconsider? JACC. 2015 in press. - PubMed
    1. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circulation research. 2011;109:923–40. - PMC - PubMed

Publication types

MeSH terms